Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
NCT05000684
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
67
Enrollment
OTHER
Sponsor class
Conditions
Advanced Lung Cancer
Interventions
DRUG:
JS004 in combination with toripalimab
Sponsor
Shanghai Junshi Bioscience Co., Ltd.